Matan Levine retweeted
Remember this dataset that you have, that you always said you have to find time to sit down and analyze? Now, LLM agents can assist you! We have built a GUI app for #datatopaper that allows easy data uploading, overseeing and reviewing. Check it out: github.com/Technion-Kishony-…
Matan Levine retweeted
1/n Can LLMs perform scientific research? And, can they do so while enhancing key scientific values including transparency, traceability & verifiability? Check out our preprint on the "data-to-paper" platform. w the amazing @TalIfargan @LostInTranscrip arxiv.org/abs/2404.17605
Matan Levine retweeted
Introducing "data-to-paper": autonomous AI research! We've let it play with the large CDC Health Survey Dataset. Went to lunch. When back, it had already chosen several research topics, wrote data analysis codes, interpreted results and wrote 5 transparent, reproducible papers.
Matan Levine retweeted
Just presented Quibbler at @PyData, announcing the "Quibble" competition - the best short quib-based app, demonstrating elegant coding, fun cool interactive graphics, and interesting use cases. Prizes for the first three places.
github.com/Technion-Kishony-…
kishony.technion.ac.il/best-…
Matan Levine retweeted
Excited to launch Quibbler, an open-source Python package for interactive data analysis. Fun to use. Nothing to learn. Your standard code effortlessly comes to life! With the amazing Maor Kern, @kmaork. github.com/Technion-Kishony-…, #python, #data
After noticing that viral-load protective effectiveness is waning over time post 2nd dose and then restored with a 3rd booster dose, we now observe that this regained effectiveness is declining within months after the 3rd dose:
medrxiv.org/content/10.1101/…
>>>
>>>
Caveats:
-Ct ≠ viable viral load
-Viral-load protective effectiveness ≠ effectiveness in preventing infection or severe disease
-Delta, not Omicron
With @idanyelin, @RoyKishony in collaboration with Sivan Gazit, Tal Patalon and their great team in #MaccabiTech @TechnionLive
Matan Levine retweeted
Vaccination with BNT162b2 associates with lower viral load in breakthrough infections of #SARSCoV2, but this effect disappears at 6 months post-vaccination. A 3rd #vaccine dose restores the reduction in viral load @RoyKishony @TechnionLive #COVID19 nature.com/articles/s41591-0…
Matan Levine retweeted
Viral load, Delta infections, vaccinations and boosters
A new preprint suggests that viral load (by PCR Ct) of Pfizer breakthrough infections in initially much reduced (15-fold) but increases significantly by 3 months, and is reduced after a booster shot
medrxiv.org/content/10.1101/…
Matan Levine retweeted
מחקר ישראלי חדש, שת"פ של טכניון @RoyKishony תל-אביב ומכבי.
מראה איך העומס הנגיפי (הערכה לפי ערכי Ct בבדיקת PCR) מושפע לאורך זמן אצל מחוסנים שנדבקו בקורונה.
רואים עליה בעומס נגיפי ככל שעובר זמן ממנה 2, אבל מנה 3 מפחיתה חזרה לרמה כמעט כמו חודשיים אחרי מנה 2
medrxiv.org/content/10.1101/…
Matan Levine retweeted
Pfizer’s #COVID vaccination protects unvaccinated individuals in the community. great teamwork with Oren Milman, @idanyelin Noga Aharoni @TechnionLive together with Tal Patalon and her fantastic team at #MaccabiTech
nature.com/articles/s41591-0…
Matan Levine retweeted
Breakthrough infections of #SARSCoV2 occurring 12 or more days after the first dose of the #BNT162b2 #mRNA #vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting the vaccine might reduce infectiousness.
nature.com/articles/s41591-0…
Matan Levine retweeted
What an amazing day for Israeli science. 3 ground-breaking studies published yesterday in @nature are coming from Israel. Diverse topics: growing babies in an artificial womb, bacteria messing up our immune system in cancer, a computer that can debate... Kudos to all 👏👏👏
Matan Levine retweeted
Daily resolution of Pfizer’s #COVID vaccine: full protectiveness only following day 35. 99.3% [CI 95.3-99.9], but decreasing with age and comorbidities, in particular, type 2 diabetes. @idanyelin #MaccabiTech, @TechnionLive
medrxiv.org/content/10.1101/…











